share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

諾和諾德 | 6-K:諾和諾德-股票回購計劃
美股sec公告 ·  06/10 21:33
牛牛AI助理已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. As part of a 12-month plan to buy back shares worth up to DKK 20 billion, the company initiated a specific repurchase phase on May 6, 2024, with the intention to acquire B shares for up to DKK 2.2 billion between May 7, 2024, and August 5, 2024. Since the last update on June 3, 2024, Novo Nordisk has purchased an additional 154,000 B shares at an average price of DKK 950.28, amounting to a total transaction value of DKK 146,319,451. This brings the accumulated repurchases under the current program to 786,545 B shares, totaling DKK 724,234,837. As of June 7, 2024, the company has acquired 9,520,795 B shares at an average price of DKK 866.73 since the beginning of the repurchase plan, representing a total spend of DKK 8,251,969,609. Novo Nordisk now holds 10,886,359 B shares as treasury shares, which is 0.2% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. As part of a 12-month plan to buy back shares worth up to DKK 20 billion, the company initiated a specific repurchase phase on May 6, 2024, with the intention to acquire B shares for up to DKK 2.2 billion between May 7, 2024, and August 5, 2024. Since the last update on June 3, 2024, Novo Nordisk has purchased an additional 154,000 B shares at an average price of DKK 950.28, amounting to a total transaction value of DKK 146,319,451. This brings the accumulated repurchases under the current program to 786,545 B shares, totaling DKK 724,234,837. As of June 7, 2024, the company has acquired 9,520,795 B shares at an average price of DKK 866.73 since the beginning of the repurchase plan, representing a total spend of DKK 8,251,969,609. Novo Nordisk now holds 10,886,359 B shares as treasury shares, which is 0.2% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
全球領先的醫療保健公司諾和諾德表示,將繼續進行股票回購計劃,該計劃於2024年2月6日開始。作爲一項爲期12個月,價值高達200億丹麥克朗的股票回購計劃的一部分,該公司於2024年5月6日發起了特定回購階段,計劃於2024年5月7日至2024年8月5日之間以高達22億丹麥克朗的價格收購B股。自2024年6月3日最後更新以來,諾和諾德已經額外購買了154000股B股,平均價格爲950.28丹麥克朗,總交易金額爲1.46319451億丹麥克朗。這使當前計劃下的回購額度累計到786545股B股,總價值爲7.24234837億丹麥克朗。截至2024年6月7日,自回購計劃開始以來,該公司以平均價格866.73丹麥克朗購買了9520795股B股,總花費達到82.51969696億丹麥克朗。諾和諾德現在持有10886359股B股作爲空庫存,佔股本的0.2%。該公司的股票在納斯達克哥本哈根和紐約證券交易所上市。
全球領先的醫療保健公司諾和諾德表示,將繼續進行股票回購計劃,該計劃於2024年2月6日開始。作爲一項爲期12個月,價值高達200億丹麥克朗的股票回購計劃的一部分,該公司於2024年5月6日發起了特定回購階段,計劃於2024年5月7日至2024年8月5日之間以高達22億丹麥克朗的價格收購B股。自2024年6月3日最後更新以來,諾和諾德已經額外購買了154000股B股,平均價格爲950.28丹麥克朗,總交易金額爲1.46319451億丹麥克朗。這使當前計劃下的回購額度累計到786545股B股,總價值爲7.24234837億丹麥克朗。截至2024年6月7日,自回購計劃開始以來,該公司以平均價格866.73丹麥克朗購買了9520795股B股,總花費達到82.51969696億丹麥克朗。諾和諾德現在持有10886359股B股作爲空庫存,佔股本的0.2%。該公司的股票在納斯達克哥本哈根和紐約證券交易所上市。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。